Revumenib (SYNDX-5613) demonstrated comparable security and efficacy in pediatric sufferers with KMT2A-rearranged acute leukemia to that noticed in grownup sufferers, based on information...
Eric Winer, MD, medical director, Grownup Leukemia, institute doctor, Dana-Farber Most cancers Institute; assistant professor, medication, Harvard Medical College, discusses the rationale for the section...
Moral assertionOur analysis complies with all related moral laws and was authorized by the Medical Moral Committee of the Erasmus College Medical Heart...
